Kopran Limited

NSE KOPRAN.NS

Kopran Limited Capital Expenditure for the year ending March 31, 2024: USD -6.79 M

Kopran Limited Capital Expenditure is USD -6.79 M for the year ending March 31, 2024, a 8.61% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Kopran Limited Capital Expenditure for the year ending March 31, 2023 was USD -7.43 M, a -33.41% change year over year.
Kopran Limited Capital Expenditure for the year ending March 31, 2022 was USD -5.57 M, a -66.97% change year over year.
Kopran Limited Capital Expenditure for the year ending March 31, 2021 was USD -3.33 M, a -78.80% change year over year.
Kopran Limited Capital Expenditure for the year ending March 31, 2020 was USD -1.86 M, a 58.69% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

NSE: KOPRAN.NS

Kopran Limited

CEO	Mr. Surendra Shrikrishna Somani B.Com.
IPO Date	July 1, 2002
Location	India
Headquarters	Parijat House
Employees	842
Sector	Health Care
Industries Pharmaceuticals

Description

Kopran Limited, an integrated pharmaceutical company, manufactures and sells active pharmaceutical ingredients and finished dosage forms in India and internationally. The company offers its products in various dosage forms, including tablets, capsules, dry powder, suspension, and injectables. It also provides active pharmaceutical ingredients in the categories of macrolide, antibacterial, anticonvulsant, anti-hypertensive, anti-helmentics, anti-histamine, anti-acne, anti-infective, urological, anti-thrombotic, antidiabetic, pain management, gastroenterology, and cardiovascular. The company was incorporated in 1958 and is headquartered in Mumbai, India.

Key trends

Past 5 years